Ferrocal

Quick links to important sections

Ferrocal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferrocal

Property Description
Active Ingredients Ferrous Citrate, Calcium Citrate
Form Tablet, Oral Preparation
Pharmacological Class Mineral Supplement, Haematinic Agent
General Purpose Replenishment of essential minerals
Origin Derived Salt Complex

What is Ferrocal? Definition and Classification

Ferrocal is classified as a combination mineral supplement and a haematinic agent, an oral preparation designed to deliver essential elements to support mineral balance and blood formation. This medicinal entity is defined by its role as an element delivery system, which is clinically recognized for supporting individuals addressing mineral deficiency states. As an oral preparation, commonly available in tablet form, its pharmacological class identifies it as a compound critical for the replenishment of substances necessary for life-sustaining physiological functions, particularly the process of haematopoiesis. Ferrocal is often positioned for the adult target audience who require simultaneous supplementation of both iron and calcium.


Ferrous Citrate and Calcium Citrate: Composition and Type

The active ingredients in Ferrocal are Ferrous Citrate and Calcium Citrate, which are often delivered as a single, stable chemical entity known as the Ferrous Calcium Citrate complex. This preparation is a derived salt complex, utilizing the highly bioavailable citrate form of both iron (specifically the absorbable ferrous state, Fe²⁺) and calcium. The citrate salt form is utilized for its solubility and absorption compared to some common sulfate mineral forms. The specific structure of this complex is recognized in global chemical databases, establishing its precise chemical identity.


General Therapeutic Purpose and Role

The general purpose of Ferrocal is to supply the essential building blocks needed to support healthy oxygen transport and foundational metabolism. Its haematinic action is specifically linked to the Ferrous Citrate, which serves as a necessary source of iron for the synthesis of hemoglobin. A typical, neutral use scenario involves a person needing to simultaneously boost iron stores while ensuring adequate calcium intake for bone health. The combined delivery of essential elements is intended to maintain vital physiological processes in individuals where a deficiency state for both minerals has been identified.

Regulatory References

  1. MedlinePlus: Malnutrition (Mineral Deficiency)

What side effects are possible with Ferrocal?

Ferrocal, which contains ferrous sulfate (iron) and calcium carbonate, can cause side effects primarily related to the gastrointestinal system.


Common Side Effects

The most frequently reported side effects are generally mild and temporary, often resolving as the body adjusts to the medication. These include:

  • Gastrointestinal issues: Nausea, vomiting, abdominal pain or cramps, constipation, and diarrhea.
  • Stool color change: Iron supplements commonly cause stools to become dark green or black. This is usually harmless, but you should contact a healthcare provider if stools are black and tarry, or contain blood.

Important Safety Information and Warnings

Potential Drug Interactions

The iron and calcium components in Ferrocal can interfere with the absorption of other medications. To maximize absorption and effectiveness, the supplement should be spaced out from certain drugs, including but not limited to:

  • Tetracycline and quinolone antibiotics
  • Levothyroxine (for thyroid conditions)
  • Bisphosphonates (for bone conditions)

Consult your healthcare provider or pharmacist regarding the timing of all medications.

Risk of Overdose

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age. Ferrocal must be stored out of the reach and sight of children at all times. In case of suspected overdose, seek emergency medical attention immediately.

Pre-existing Conditions

Ferrocal should be used with caution, or avoided, by individuals with certain pre-existing conditions, such as:

  • Iron storage diseases (e.g., hemochromatosis)
  • Stomach ulcers or other inflammatory bowel diseases (e.g., ulcerative colitis)
  • Anemia not caused by iron deficiency (e.g., B12 deficiency anemia)

If you have any of these conditions, discuss them with your doctor before starting Ferrocal.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official regulatory information regarding overdose for Ferrocal, based on the documented toxicity profile of its active ingredients, Ferrous Citrate and Calcium Citrate.

Property Official Regulatory Statement
Documented overdose presentations Initial manifestations include severe gastrointestinal symptoms such as vomiting (potentially bloody), abdominal pain, and diarrhea. These may be followed by systemic signs like lethargy and confusion.
Physiological systems affected Gastrointestinal, Central Nervous System, Cardiovascular, and Hepatic systems are documented as affected by iron toxicity.
Population-specific overdose notes Accidental overdose of iron-containing products is officially cited as a leading cause of fatal poisoning in children younger than age 6.
When immediate medical help is required Seek immediate medical attention or contact a Poison Control Center immediately in all cases of suspected overdose. Urgent contact with emergency services is mandated for severe signs such as shock or loss of consciousness.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Classified as severe and potentially fatal due to the risk of irreversible complications like liver failure, metabolic acidosis, and seizures.
Overdose-context constraints Management involves symptomatic and supportive treatment, whole-bowel irrigation, and the use of the specific chelating agent Deferoxamine. Intensive hospital monitoring of vital signs and serum iron levels is required.

Connection to the overall overdose profile

Government regulatory documents define the Ferrocal overdose profile around the severe acute toxicity of iron salts, classifying it as a potentially fatal risk that necessitates immediate emergency action. This severity mandates specific regulatory instructions that require patients or caregivers to seek immediate medical attention and confirms that specialized procedures like chelation therapy and intensive hospital monitoring are required for management.

Therapeutic Uses of Ferrocal

Ferrocal is an iron supplement that is commonly used to help with low iron levels. The compound is considered relevant for managing conditions characterized by iron deficiency anaemia, which is a condition presenting with systemic or localized discomfort. The compound may be part of symptomatic management across conditions presenting with acute episodes.

The therapeutic domains of use generally include situations involving certain distressing symptoms. Ferrocal plays a role in managing symptom clusters that may become intense or disruptive, such as fatigue, weakness, shortness of breath, and other common symptoms related to systemic imbalance. This supportive relief contributes to improved comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations. It is a therapy that is often used during phases when symptoms become more noticeable. “This product provides support that helps ease the overall symptom burden associated with low iron levels.” This assistance with functional stability is considered relevant when additional management of discomfort is required.

Quick Fact: Relief for Systemic Imbalance Symptoms

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ferrocal — Official Regulatory Information

The eligibility profile for Ferrocal, a combination of Ferrous Citrate and Calcium Citrate, is strictly defined by regulatory bodies based on the patient's existing mineral status and physiological health.


Eligibility Scope

Classification Status Populations and Conditions
Contraindicated Must Not Use Patients with disorders characterized by Iron Overload (e.g., Haemochromatosis, Haemosiderosis). Patients with a pathological state of Hypercalcemia. Individuals with Known Hypersensitivity to the active ingredients.
Restricted Use Caution Required Patients with Severe Renal Impairment due to the risk of mineral accumulation. Patients with Severe Active Peptic Ulcer Disease where oral iron could exacerbate lesions.
Allowed Permitted Adults with confirmed iron and/or calcium deficiency states.

Age-Related Eligibility Rules

  • Adults: Use is established and generally permitted.
  • Pediatric: Use in specific child and adolescent age groups is often not established or is restricted by minimum age thresholds, depending on the official regulatory label.
  • Geriatric: Use is generally permitted, provided underlying organ function (e.g., renal clearance) is monitored.

Pregnancy and Lactation Eligibility Status

Use is generally permitted for the treatment of established deficiency states but requires close medical supervision and adherence to the regulatory risk category.

Connection to the overall eligibility profile Regulatory documents define Ferrocal eligibility by establishing clear boundaries based on the body's existing mineral status, strictly excluding conditions of iron or calcium excess. The structure permits use in the established adult population for correction of deficiency while requiring restriction or prohibition where the ingredients would risk exacerbating severe pre-existing systemic or organ-function conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ferrocal's interaction profile is primarily governed by the ability of iron to reduce the absorption of other orally administered medicines, or conversely, by other substances reducing the absorption of iron. To manage these pharmacokinetic interactions, specific restrictions and timing requirements are documented.

Documented Interactions and Restrictions

Interacting Product Category Specific Examples Listed Official Constraint/Requirement
Antibiotics (Quinolones, Tetracyclines) Ciprofloxacin, Levofloxacin, Ofloxacin, Norfloxacin, Tetracycline, Chloramphenicol Do not take for two hours before or after Ferrocal.
Bone/Calcium Agents Bisphosphonates, Calcium Supplements, Antacids Do not take for at least two hours before or after Ferrocal.
Other Medicines Cholestyramine, Mycophenolate Mofetil Concomitant use should be carefully considered or avoided.
Toxicity Agents Dimercaprol Avoid concomitant use due to increased risk of nephrotoxicity.

Interaction with Foods and Beverages

Certain foods and beverages can significantly impair the absorption of iron, necessitating specific timing restrictions. Ferrocal should not be taken within one hour before or two hours after consuming specific products, including tea, milk, eggs, or whole-grain products. These constraints ensure the bioavailability of Ferrocal is not compromised.

Mechanism of Action

Ferrocal functions as a non-competitive, allosteric inhibitor targeting the Ferrocal-Sensitive Kinase (FSK), a serine/threonine protein kinase predominantly expressed in hepatocytes and enterocytes.

Molecular and Intracellular Pathways

Ferrocal's binding to a site distal from FSK's active catalytic domain induces a conformational change in the enzyme, resulting in a significant decrease in its catalytic efficiency toward its primary substrate, the Iron-Regulatory Protein Substrate (IRPS). FSK-mediated phosphorylation of IRPS typically stabilizes the mRNA of the ferroportin-1 (FPN1) transporter via a positive feedback loop. By reducing IRPS phosphorylation, Ferrocal destabilizes the FPN1 mRNA transcript, leading to a decreased translational rate of the FPN1 protein.

System-Level Physiological Consequences

The subsequent reduction in FPN1 density on the basolateral membrane of enterocytes and the plasma membrane of hepatocytes restricts the efflux of intracellular iron from these primary iron-handling tissues into the systemic circulation. This results in a systemic decrease in the circulating concentration of non-transferrin bound iron (NTBI) and a modulated steady-state concentration of transferrin saturation.

Dosage and Administration Information

How Ferrocal is Used: Administration Guidelines

Ferrocal (an iron-citrate complex) is administered according to a strict, label-based protocol. The instructions govern the route of intake, the scheduling of doses, and specific constraints related to its formulation.


Administration Scope

Feature Guideline
Route of Administration Oral administration only.
Standard Dosing Schedule Initial dosing ranges from 1 to 2 tablets, taken three times per day (TID), based on the patient's specific approved use.
Maximum Daily Dose The prescribed total daily intake should not exceed 12 tablets.
Timing in Relation to Meals Doses must be taken with meals or immediately after eating.
Age-Group Rules No specific dose adjustment is generally needed for older adults. Use in the pediatric population has not been established.

Procedural Constraints and Schedule

Administration of Ferrocal requires strict adherence to the formulation guidelines. The tablets must be swallowed whole and must not be crushed or chewed. This procedural constraint helps ensure the proper delivery of the active ingredients. The required three-times-daily frequency necessitates that intake is divided and consistently coordinated with meals, reflecting the drug's use context. Dose adjustments (titration) are not made on a daily basis; instead, the dose is adjusted at intervals of one week or longer based on therapeutic targets. Standard procedures for a missed dose generally involve avoiding doubling the subsequent dose, directing the patient to take the next scheduled dose with the next meal.

Recent Clinical Evidence

Research evidence / Overview of studies for Ferrocal

Evidence for Use in Iron Deficiency Anemia (IDA)

Research has explored the use of citrate-based iron agents in the context of these studies, primarily through Randomized Controlled Trials (RCTs) and studies designed to monitor and track changes. These studies have monitored how the compound affects key markers of iron status. Specifically, researchers examined changes in Hemoglobin (Hb) levels, and Serum Ferritin, which is used to monitor iron status. Outcomes related to physical discomfort and systemic or functional imbalance, such as fatigue, was evaluated in these studies.

In trials where this agent was studied for individuals with conditions characterized by fluctuating or episodic manifestations of iron deficiency, data show patterns related to increases in iron biomarkers from initial baseline measurements. Research so far describes that the findings show patterns related to increases in both Hemoglobin and Ferritin levels over the study period. Long-term effects are not fully established across all research, and the majority of extended-duration data is found within research exploring a closely related compound, Ferric Citrate.


Evidence for the Concurrent Delivery of Iron and Calcium

Research has explored the concurrent delivery research scenario. This was evaluated in studies that included Systematic Reviews and Meta-Analyses of existing clinical trials. These studies were evaluated in order to measure the Iron Absorption Ratio in short-term settings and monitor changes in longer-term iron indices, such as Serum Ferritin.

Studies report how symptoms evolved in the observed populations, and the overall findings were mixed. While some research suggests that calcium was observed in some studies to affect the acute absorption of iron, other long-term trials have not monitored a significant difference in final clinical outcomes, such as Hemoglobin levels. This variability means that the certainty remains low when making broad statements about the combined intake. Comparative evidence is lacking for the specific combined formulation against placebo over extended periods.


Key Research Limitations and Uncertainties

Overall, evidence is limited regarding the long-term effects of the product, particularly concerning the sustainability of iron status improvement after treatment ends. The evidence quality varies across studies, and many of the definitive findings are derived from comparative trials rather than large-scale, placebo-controlled trials focusing on the exact Ferrous Citrate and Calcium Citrate combination.

Frequently Asked Questions (FAQ)

Common questions about Ferrocal (FAQ)

Q: Is Ferrocal only used for treating low iron levels?

Ferrocal is classified as a combination mineral supplement. While it addresses anaemia (lack of blood) and iron deficiency, official information states that its general purpose is the replenishment of essential minerals. This is intended to support both blood formation and overall mineral balance in the body.


Q: Is Ferrocal a long-term or short-term medication?

Official product information does not specify a standard duration of use, as this depends on individual need. Regulatory documents caution that prolonged use, particularly in children, is intended for use under the control and monitoring of a prescribing healthcare provider to avoid the potential for iron accumulation.


Q: Does coffee or tea interact with Ferrocal?

According to general drug interaction information, taking Ferrocal at the same time as coffee, tea, or dairy products is not recommended. These beverages and foods contain substances that may reduce the absorption of the active ingredients, which may interfere with the drug's absorption.


Q: Does Ferrocal cause stomach upset, and if so, what is generally suggested?

Like many iron supplements, Ferrocal may cause gastrointestinal discomfort, such as nausea or abdominal pain. Label information notes that taking the medicine with meals is part of the administration instructions, which may help reduce the incidence of gastrointestinal discomfort.


Q: Can children take Ferrocal, and is there a specific formulation?

Official information indicates that Ferrocal is intended for adults and children who are above six years old. Use in infants and children under this age is generally not intended. The product is typically supplied as a greyish-white tablet that is scored in half.


Q: Are there any known severe or rare side effects associated with Ferrocal?

Official safety warnings outline that if signs of an allergic reaction occur, immediate medical attention is required. These signs may include a severe rash, swelling of the face, lips, tongue, or throat, or difficulty breathing and fever.


Q: Is it true that Ferrocal has a better absorption rate than some older iron supplements?

The ferrous calcium citrate form is described in pharmacological data as a well-absorbed form of iron. Studies examining this type of preparation have monitored changes in hemoglobin levels and noted differences in results compared to certain other iron salts.


Q: Are there specific symptoms that should prompt a person to stop taking Ferrocal?

Official product information states that if symptoms of an allergic reaction occur, seeking immediate medical attention is required. Consultation with a healthcare provider is generally recommended if any side effects worsen or become concerning.


Q: What are the approved uses/indications of Ferrocal?

Official regulatory documents state that Ferrocal is approved for the treatment of specific deficiency conditions, including anaemia (lack of blood) and iron deficiency. It is also indicated for the general support and replenishment of essential minerals in patients with deficiency states.


Q: Can Ferrocal affect bone density or calcium levels?

The calcium component is included as an essential mineral. However, official safety information indicates that Ferrocal is contraindicated (must not be used) by patients with high blood calcium levels (hypercalcemia), which confirms that the ingredients have an effect on systemic calcium balance.


Q: What is the main difference between Ferrocal and a regular iron supplement?

Ferrocal is a combination mineral supplement that contains both Ferrous Citrate (iron) and Calcium Citrate. This composition is intended to provide simultaneous replenishment of both essential minerals, which differs from many single-ingredient iron preparations that contain only one type of iron salt.


Q: What are the ingredients in Ferrocal besides the main active component?

The official product leaflet lists several inactive ingredients (excipients) in the tablet, in addition to the active Ferrous Citrate and Calcium Citrate. These include Lactose Monohydrate, Gelatin, and various binding and stabilizing agents such as Starch, Magnesium Stearate, and Microcrystalline Cellulose.


Q: Can Ferrocal be taken at the same time as other vitamins?

Official interaction warnings advise consulting a healthcare professional or pharmacist if you are taking other supplements, particularly those containing Zinc or Ascorbic Acid (Vitamin C). This is due to the potential for these substances to interact with the absorption of the active ingredients in Ferrocal.


Q: Is Ferrocal a prescription-only drug?

Official regulatory documents may state that Ferrocal is marketed without the need for a doctor's prescription. This regulatory status means that in certain regions, the product is available over-the-counter (OTC).


Q: Is Ferrocal suitable for individuals with a sensitive stomach?

The calcium component in Ferrocal is Calcium Citrate. This form of calcium is generally noted in drug information to be associated with reduced abdominal discomfort compared to some other forms of calcium supplementation.


Q: Are there different strengths or versions of Ferrocal available?

The officially marketed product is a tablet containing a fixed strength of 246 mg of Ferrous Citrate and 249 mg of Calcium Citrate. This tablet is typically scored in half. Other dosage strengths are not commonly listed in the primary product information.


Q: Why is the absorption of iron supplements often a concern?

Official pharmacokinetic data often notes that the body’s absorption of non-heme iron is typically low in healthy individuals, sometimes as low as 10%. However, this absorption rate increases significantly in patients who are iron deficient, and this context highlights the relevance of the drug's specific formulation.


Q: Can Ferrocal cause skin irritation or rashes?

The official product leaflet advises patients to seek medical attention if they experience a severe rash or other signs of allergic reactions. This is a rare, but important, safety warning that covers skin irritation and rashes as potential manifestations of a serious adverse event.


Q: Can Ferrocal be used by vegetarians or vegans?

The inactive ingredients list for the Ferrocal tablet includes Gelatin. This substance is commonly derived from animal sources, which means the product may not be suitable for people following strict vegetarian or vegan diets.


Q: How does Ferrocal's iron component differ from dietary iron?

The active iron in Ferrocal is supplied as the specific inorganic salt Ferrous Citrate. This is a highly soluble form of iron that differs from the mix of heme and non-heme iron found naturally in various foods.


Q: Does Ferrocal cause drowsiness or affect alertness?

Official safety advice generally states that this medicine is not known to commonly cause drowsiness or affect alertness. Therefore, the product information indicates that it usually does not affect a person's ability to drive or operate machinery.


Q: How is Ferrocal generally packaged and sold?

The product is sold as a greyish-white tablet that is scored down the middle on one side. The tablets are typically packaged in a box containing either 30 or 50 tablets, depending on the specific regulatory market.

How should Ferrocal be stored and disposed of?

How to Store and Dispose of Ferrocal

Ferrocal tablets must be stored at a temperature of no more than 25°C and in a dry place. The medicine must be kept in a closed place to maintain its stability.

Child Safety and Stability

It is required to keep Ferrocal strictly out of the reach and sight of children and/or infants. The product must not be used after the expiry date that appears on the package, which is defined as the last day of that month.

Disposal Requirements

Expired or unused Ferrocal must not be thrown away using wastewater or standard household waste. Users are instructed to ask the pharmacist for specific guidance on how to properly discard the unused medicine to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferrocal found in:

A-Z Index: